References
-
Authi, K. S., Localization of the [
$^{32}P$ ]IP3 binding site on human platelet intracellular membranes isolated by high-voltage free- flowelectrophoresis. FEBS Lett., 298, 173-176(1992) https://doi.org/10.1016/0014-5793(92)80049-M - Becker, R. C., Thrombin antagonists and antiplatelet agents. Am. J. Cardiol., 69, 39A-51A (1992) https://doi.org/10.1016/0002-9149(92)91170-9
- Eidt, J. F., Allison, P., Noble, S., Ashton, J., Golino, P., McNatt, J., Buja, L. M. and Willerson, J. T., Thrombin is an important mediatorof platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest., 84, 18-27 (1989) https://doi.org/10.1172/JCI114138
- Gustafsson, D., Antonsson, T., Bylund, R., Eriksson, U., Gyzander, E., Nilsson, I., Elg, M., Mattsson, C., Deinum, J., Pehrsson, S., Karlsson, O., Nilsson, A. and Sorensen, H., Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost., 79, 110-118 (1998) https://doi.org/10.1055/s-0037-1614245
- Hirsh, J., Heparin. N. Engl. J. Med., 324, 1565-1574(1991) https://doi.org/10.1056/NEJM199105303242206
- Hughes, P. E. and Pfaff, M., Integrin affinity modulation. Trends Cell Biol., 8, 359-364 (1998) https://doi.org/10.1016/S0962-8924(98)01339-7
- Hursting, M. J., Alford, K. L., Becker, J. C., Brooks, R L., Joffrion, J. L., Knappenberger, G. D., Kogan, P. W., Kogan, T. P., McKinney, A. A and Schwarz, R. P., Jr., Novastan(brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin. Thromb. Hemost., 23, 503-516 (1997) https://doi.org/10.1055/s-2007-996128
- Kelton, J. G., Sheridan, D., Santos, A, Smith, J., Steeves, K., Smith, C., Brown, C. and Murphy, W G., Heparin-induced thrombocytopenia: laboratory studies. Blood, 72, 925-930 (1988)
- Lee, S. K., Lee, J. Y., Lee, M. Y., Chung,S. M. and Chung, J. H., Advantagesof calciumgreen-1 over other fluorescent dyes in measuring cytosolic calcium in platelets. Anal. Biochem, 273, 186-191 (1999) https://doi.org/10.1006/abio.1999.4212
- Matsuo, T., Koide, M. and Kario, K., Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin. Thromb. Hemost., 23, 517-522 (1997) https://doi.org/10.1055/s-2007-996129
- Oh, Y. S., Yun, M., Hwang, S. Y., Hong, S., Shin, Y., Lee, K., Yoon, K. H., Yoo, Y. J., Kim, D. S., Lee, S. H., Lee, Y. H., Park, H. D., Lee, C. H., Lee, S. K. and Kim, S., Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor. Bioorg. Med. Chem. Lett., 8, 631-634 (1998) https://doi.org/10.1016/S0960-894X(98)00079-1
- Ripka, W. C., New thrombin inhibitors in cardiovascular disease. Curr. Opin. Chem. Biol., 1, 242-253 (1997) https://doi.org/10.1016/S1367-5931(97)80016-6
- Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809 (1993) https://doi.org/10.1038/362801a0
- Turpie, A. G., Weitz, J. I. and Hirsh, J., Advances in antithrombotic therapy: novel agents. Thromb. Haemost., 74, 565-571 (1995)
- Van Nueten, J. M., Leysen, J. E., de Clerck, F. and Vanhoutte, P.M., Serotonergic receptor subtypes andvascular reactivity. J. Cardiovasc. Pharmacol., 6 Suppl4, S564-S574(1984) https://doi.org/10.1097/00005344-198406004-00003
- Vanhoutte, PM., 5-hydroxytryptamine and vascular disease. Fed. Proc., 42, 233-237 (1983)
- Vanhoutte, P. M. and Houston, D. S., Platelets, endothelium, and vasospasm. Circulation, 72, 728-734 (1985) https://doi.org/10.1161/01.CIR.72.4.728
- Weitz, J. I., Biological rationale for the therapeutic role of specific antithrombins. Caron. Artery Dis,. 7, 409-419 (1996) https://doi.org/10.1097/00019501-199606000-00003
- Zimmerman, G. A., Elstad, M. R., Lorant, D. E., Mcintyre, T M., Prescott, S. M., Topham, M. K., Weyrich, A. S. and Whatley, R. E., Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Adv. Exp. Med. Biol., 416, 297-304 (1996)